Compare Davita Inc (DVA) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Icl Group Ltd — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Icl Group Ltd trades at $5.01 (market cap $6.60B). The key difference: Davita Inc is the larger of the two by market cap, and Icl Group Ltd pays a 4.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Icl Group Ltd for 56 Days on average.
| DVA | ICL | |
|---|---|---|
Market Cap | $11.28B | $6.60B |
Volume | 650,294 | 824,784 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $6.84 |
52-Week Low | $103.87 | $4.80 |
Typical Hold Time | 113 Days | 56 Days |
Enterprise Value | $24.00B | $9.24B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
ICL Group trades at $5.00, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The company shows stable revenue around $7.2B but declining net margins from 21.55% in 2022 to 3.15% in 2025. Analyst consensus is neutral with 100% hold ratings and a $6.08 price target, suggesting 22% upside. Recent news highlights dividend strength and Q2 2026 earnings beat.
ICL offers value with low P/S (0.85) and EV/EBITDA (6.77) ratios, but faces profitability pressures from industry headwinds. The primary risk is margin compression from higher input costs, while institutional buying and dividend yield provide support. The stock presents a cautious opportunity for value investors willing to withstand sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
